#Canada #Cambridge #ALS #NeuroSense #PrimeC

NeuroSense Advances PrimeC Toward Submission for ALS

NeuroSense Therapeutics Ltd., traded on NASDAQ under the ticker symbol NRSN, is making significant strides in its development efforts for PrimeC, targeting amyotrophic lateral sclerosis (ALS). The company recently announced its intent to submit a New Drug Submission (NDS) to Health Canada, aligned with the agency on the pathway for potential approval.

Key Developments in Clinical Trials

The decision to move forward follows a constructive meeting with Health Canada during which NeuroSense provided detailed updates from its Phase 2b PARADIGM clinical trial. This study yielded considerable evidence supporting PrimeC's efficacy, including achieving its primary endpoint focused on the TDP-43 biomarker, a critical marker in ALS progression. Studies indicated a statistically significant median survival benefit of 14.9 months, reflecting the long-term potential of PrimeC as a treatment option.

Data also showed a hazard ratio of 0.35, showcasing a promising long-term outcome for ALS patients treated with PrimeC. The team presented various supportive analyses and clinical perspectives, including insights from prominent Canadian ALS specialists, all contributing to a strengthened submission package designed to highlight PrimeC's potential in addressing ALS-related challenges.

Regulatory Path Forward

Looking ahead, CEO Alon Ben-Noon emphasized the significance of this regulatory strategy milestone for PrimeC. He believes that the robust evidence derived from new clinical data greatly bolsters their confidence in PrimeC's capacity to meet the pressing needs of ALS patients, given the disease's currently unmet treatment needs. NeuroSense expresses gratitude towards Health Canada for their constructive engagement throughout the preparation for the NDS filing and anticipates further productive collaboration as the process unfolds.

Background on NeuroSense and PrimeC

NeuroSense is a biotechnology firm focusing on creating innovative treatments for debilitating neurodegenerative diseases like ALS and Alzheimer’s Disease. PrimeC, the company’s leading candidate, is notably an oral therapy developed to target several essential biological pathways that contribute to neurodegeneration and inflammation, recognizing the multifaceted nature of ALS.

The drug employs a unique mixed formulation utilizing two FDA-approved medications: ciprofloxacin and celecoxib. This combination is designed to synergistically address indicators of neuron degeneration, inflammation, and other critical factors linked to ALS progression.

Furthermore, NeuroSense has recently conducted extensive analysis regarding follow-up data from the Phase 2b PARADIGM study, noting a significant deceleration in disease progression and notable biological activity across various ALS-related biomarkers. This positions PrimeC potentially as a breakthrough treatment in managing ALS symptoms.

Future Steps

In addition to submitting the NDS to Health Canada, NeuroSense has also gained clearance from the U.S. FDA to begin a pivotal Phase 3 clinical trial, known as PARAGON, which is aimed at enrolling up to 300 participants, primarily within the United States. These upcoming steps signify a promising advance in the clinical development of PrimeC, which could critically alter the landscape of ALS treatment.

About ALS

ALS, a severe neurodegenerative disorder, leads to total paralysis and sadly results in death within 2-5 years from diagnosis. Each year, thousands of cases are reported in the U.S., placing a heavy burden on families and the healthcare system. With the number of patients projected to increase significantly in the coming years, advancements like those pursued by NeuroSense are desperately needed.

In conclusion, the progress made by NeuroSense with PrimeC represents a hopeful step forward for those impacted by ALS, aiming for a future where effective treatments can significantly improve quality of life and clinical outcomes.